Logo of The Journal of Bone & Joint Surgery (Br)
Quick search:        
          Advanced Search
Guest Access | Sign In
Journal of Bone and Joint Surgery - British Volume, Vol 87-B, Issue 3, 416-420.
doi: 10.1302/0301-620X.87B3.14665  
Copyright © 2005 by British Editorial Society of Bone and Joint Surgery
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow FrenchSpanishItalianRomanianPolishRussianCzech
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow My Folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (16)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bobyn, J. D.
Right arrow Articles by Tanzer, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bobyn, J. D.
Right arrow Articles by Tanzer, M.

Zoledronic acid causes enhancement of bone growth into porous implants

J. D. Bobyn, PhD, Associate Professor1; S. A. Hacking, MEng, Graduate Student2; J. J. Krygier, CET, Technical Director3; E. J. Harvey, MD, Assistant Professor4; D. G. Little, MD, Orthopaedic Research Unit5; and M. Tanzer, MD, Associate Professor2

1 Departments of Surgery and Biomedical Engineering
2 Department of Biomedical Engineering McGill University, Montreal, Quebec, Canada.
3 Jo Miller Orthopaedic Research Lab Montreal General Hospital, Montreal, Quebec, Canada.
4 Division of Orthopaedics, Department of Surgery
5 The Children’s Hospital at Westmead, Westmead, New South Wales, Australia.

Correspondence should be sent to Dr J. D. Bobyn at Montreal General Hospital Research Institute, Room LS1-409, 1650 Cedar Avenue, Montreal, Quebec H3G 1A4, Canada; e-mail: jdbobyn{at}hotmail.com

The effect of zoledronic acid on bone ingrowth was examined in an animal model in which porous tantalum implants were placed bilaterally within the ulnae of seven dogs. Zoledronic acid in saline was administered via a single post-operative intravenous injection at a dose of 0.1 mg/kg. The ulnae were harvested six weeks after surgery. Undecalcified transverse histological sections of the implant-bone interfaces were imaged with backscattered scanning electron microscopy and the percentage of available pore space that was filled with new bone was calculated. The mean extent of bone ingrowth was 6.6% for the control implants and 12.2% for the zoledronic acid-treated implants, an absolute difference of 5.6% (95% confidence interval, 1.2 to 10.1) and a relative difference of 85% which was statistically significant. Individual islands of new bone formation within the implant pores were similar in number in both groups but were 69% larger in the zoledronic acid-treated group. The bisphosphonate zoledronic acid should be further investigated for use in accelerating or enhancing the biological fixation of implants to bone.




This article has been cited by other articles:


Home page
 J Bone Joint Surg BrHome page
J. Bruns, G. Delling, H. Gruber, C. H. Lohmann, and C. R. Habermann
Cementless fixation of megaprostheses using a conical fluted stem in the treatment of bone tumours
J Bone Joint Surg Br, August 1, 2007; 89-B(8): 1084 - 1087.
[Abstract] [Full Text] [PDF]


(c) British Editorial Society of Bone and Joint Surgery All Rights Reserved
Registered charity no: 209299     Print ISSN: 0301-620X
Hip, Knee, Trauma, Upper limb, Foot & Ankle, Paediatrics, Oncology, Spine, Arthroplasty, General